Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 December, 2024
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Procter & Gamble Health Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 21, 2024, 1:58 am

Market Cap 9,075 Cr.
Current Price 5,467
High / Low 5,850/4,637
Stock P/E40.0
Book Value 324
Dividend Yield1.10 %
ROCE45.0 %
ROE33.5 %
Face Value 10.0
PEG Ratio-11.85

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for

Competitors of

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,354 Cr. 308 390/12863.6 20.50.22 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 62.6 Cr. 84.4 94.9/26.624.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 35.9 Cr. 24.5 24.5/8.7446.6 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 86.7 Cr. 115 155/87.013.0 55.40.00 %14.4 %15.5 % 10.0
Glenmark Life Sciences Ltd 12,416 Cr. 1,013 1,335/64529.3 2072.22 %28.1 %21.1 % 2.00
Industry Average19,016.52 Cr1,181.3156.05186.300.32%16.20%16.32%6.27

All Competitor Stocks of

Quarterly Result

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Sales219285273278268296298310321301305310252
Expenses188237195216199237207201241256216208185
Operating Profit3148786269599110980458910267
OPM %14%17%29%22%26%20%31%35%25%15%29%33%27%
Other Income3235233555652
Interest0000000000000
Depreciation8777677866677
Profit before tax2644746065558710579448810063
Tax %40%22%25%25%21%25%26%27%25%32%26%28%26%
Net Profit16345545514164775930667247
EPS in Rs9.5020.4233.3627.0130.8224.8138.3546.2735.6617.9639.5043.4228.05

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023TTM
Sales6877988679409936988499271,3561,0091,1141,2301,169
Expenses5827218098558776217017231,037762846905865
Operating Profit10677598511677148204319246268325303
OPM %15%10%7%9%12%11%17%22%24%24%24%26%26%
Other Income202120222474768486618131819
Interest0000000001011
Depreciation9101323251921172930272827
Profit before tax117886783115132895234355233253314295
Tax %33%37%35%36%31%29%6%32%28%24%24%27%
Net Profit785643547994839159254177193229214
EPS in Rs47.2333.6626.0432.2747.6756.57505.2795.64153.07106.51115.98138.24128.93
Dividend Payout %5%25%23%23%23%27%87%0%150%122%45%44%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year
YoY Net Profit Growth (%)
Change in YoY Net Profit Growth (%)

No data available for trend analysis.

Growth

Compounded Sales Growth
10 Years:4%
5 Years:6%
3 Years:5%
TTM:-6%
Compounded Profit Growth
10 Years:14%
5 Years:-24%
3 Years:7%
TTM:-2%
Stock Price CAGR
10 Years:21%
5 Years:5%
3 Years:2%
1 Year:10%
Return on Equity
10 Years:28%
5 Years:27%
3 Years:32%
Last Year:33%

Last Updated: Unknown

Balance Sheet

Last Updated: September 15, 2024, 2:57 pm

MonthDec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024
Equity Capital171717171717171717171717
Reserves5065385756477171,524800890687600734522
Borrowings00000000831210
Other Liabilities125154192215258219250269275269338247
Total Liabilities6487087848799911,7591,0671,1769868881,101794
Fixed Assets85110132111115104101101104112144128
CWIP92873091711213941326
Investments24244228700000000
Other Assets5305476037117971,6399541,053843736925660
Total Assets6487087848799911,7591,0671,1769868881,101794

Reserves and Borrowings Chart

Cash Flow

MonthDec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024
Cash from Operating Activity +058310754-130235247170236228
Cash from Investing Activity +711-68-75-481,270165-32-26-22-7
Cash from Financing Activity +-5-17-12-15-22-30-883-387-289-98-418
Net Cash Flow3-1417-161,109-483-172-145116-197

Free Cash Flow

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023
Free Cash Flow106.0077.0059.0085.00116.0077.00148.00204.00319.00238.00265.00313.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthDec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024
Debtor Days384449396428302622273427
Inventory Days153162140145243154139113138124136120
Days Payable37405567128124106105209185239184
Cash Conversion Cycle154166134118179586334-49-34-69-37
Working Capital Days70746952944222239181620
ROCE %18%12%15%18%16%78%20%29%29%38%45%45%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%
FIIs5.97%6.57%6.47%6.05%6.33%6.72%7.15%7.38%7.60%6.24%6.39%6.61%
DIIs8.53%7.91%8.07%12.62%12.44%12.31%12.29%12.30%12.66%13.72%14.56%14.84%
Public33.69%33.71%33.64%29.51%29.41%29.14%28.74%28.50%27.92%28.22%27.24%26.74%
No. of Shareholders65,53766,28965,72965,14863,83161,03058,85657,91956,73056,77855,92354,792

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund596,8070.75306.1596,8072024-12-210%
HDFC Small Cap Fund - Regular Plan326,8340.66167.63596,8072024-12-21-45.24%
DSP Healthcare Fund158,7044.2381.4596,8072024-12-21-73.41%
UTI MNC Fund145,8872.8374.82596,8072024-12-21-75.56%
Sundaram Small Cap Fund74,5541.3338.24596,8072024-12-21-87.51%
UTI Healthcare Fund35,0002.117.95596,8072024-12-21-94.14%
Tata Retirement Savings Fund - Moderate Plan - Regular Plan31,0000.8615.9596,8072024-12-21-94.81%
Tata Retirement Savings Fund - Progressive Plan - Regular Plan28,8000.9114.77596,8072024-12-21-95.17%
Tata India Pharma & HealthCare Fund16,0001.098.21596,8072024-12-21-97.32%
Aditya Birla Sun Life MNC Fund - Div13,6710.27.01596,8072024-12-21-97.71%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthJun 24Jun 23Jun 22Jun 21Jun 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)121.07138.00116.00107.00153.00
Diluted EPS (Rs.)121.07138.00116.00107.00153.00
Cash EPS (Rs.)137.58155.16132.29124.60170.80
Book Value[Excl.RevalReserv]/Share (Rs.)324.24452.34371.38423.92545.99
Book Value[Incl.RevalReserv]/Share (Rs.)324.24452.34371.38423.92545.99
Dividend / Share (Rs.)260.0095.0052.50130.00230.00
Revenue From Operations / Share (Rs.)693.53740.73671.33607.67816.78
PBDIT / Share (Rs.)193.75206.67169.20159.11231.51
PBIT / Share (Rs.)177.25189.74152.88141.01213.76
PBT / Share (Rs.)164.65189.28152.63140.53213.76
Net Profit / Share (Rs.)121.07138.23115.97106.51153.06
PBDIT Margin (%)27.9327.9025.2026.1828.34
PBIT Margin (%)25.5525.6122.7723.2026.17
PBT Margin (%)23.7425.5522.7323.1226.17
Net Profit Margin (%)17.4518.6617.2717.5218.73
Return on Networth / Equity (%)37.3430.5531.2225.1228.03
Return on Capital Employeed (%)51.1339.5038.5731.3237.41
Return On Assets (%)25.3020.8321.5417.9221.61
Asset Turnover Ratio (%)1.211.231.190.930.00
Current Ratio (X)2.392.622.603.044.21
Quick Ratio (X)1.902.182.112.553.62
Inventory Turnover Ratio (X)2.382.552.772.290.00
Dividend Payout Ratio (NP) (%)0.0040.87147.43215.93287.45
Dividend Payout Ratio (CP) (%)0.0036.41129.25184.57257.59
Earning Retention Ratio (%)0.0059.13-47.43-115.93-187.45
Cash Earning Retention Ratio (%)0.0063.59-29.25-84.57-157.59
Interest Coverage Ratio (X)446.71445.55668.74330.150.00
Interest Coverage Ratio (Post Tax) (X)308.18299.01459.38222.000.00
Enterprise Value (Cr.)8138.398273.456626.398817.136112.46
EV / Net Operating Revenue (X)7.076.735.958.744.51
EV / EBITDA (X)25.3024.1223.5933.3815.91
MarketCap / Net Operating Revenue (X)7.287.096.249.214.98
Retention Ratios (%)0.0059.12-47.43-115.93-187.45
Price / BV (X)15.5711.6011.2813.207.45
Price / Net Operating Revenue (X)7.287.096.249.214.98
EarningsYield0.020.020.020.010.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of as of December 22, 2024 is: 4,389.36

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 22, 2024, is Overvalued by 19.71% compared to the current share price 5,467.00

Intrinsic Value of as of December 22, 2024 is: 4,241.25

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 22, 2024, is Overvalued by 22.42% compared to the current share price 5,467.00

Last 5 Year EPS CAGR: -3.37%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 30.25%, which is a positive sign.
  2. The company has higher reserves (728.33 cr) compared to borrowings (2.75 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (520.31 cr) and profit (244.69 cr) over the years.
  1. The stock has a high average Working Capital Days of 42.42, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 59.75, which may not be favorable.
  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in :
    1. Net Profit Margin: 17.45%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 51.13% (Industry Average ROCE: 16.07%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 37.34% (Industry Average ROE: 15.77%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 308.18
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.9
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 40 (Industry average Stock P/E: 46.07)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Procter & Gamble Health Ltd. is a Public Limited Listed company incorporated on 26/04/1967 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L99999MH1967PLC013726 and registration number is 013726. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 1114.41 Cr. and Equity Capital is Rs. 16.60 Cr. for the Year ended 30/06/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsP&G Plaza, Cardinal Gracias Road, Mumbai Maharashtra 400099investorgrievance.im@pg.com
https://www.pghealthindia.com
Management
NamePosition Held
Mr. Suresh TalwarChairman & Ind.Director
Mr. Milind ThatteManaging Director
Mr. Lokesh ChandakExecutive Director & CFO
Ms. Seema SambasivanNon Executive Director
Mr. Aalok AgrawalNon Executive Director
Mrs. Rani JadhavIndependent Director
Mr. S MadhavanIndependent Director

FAQ

What is the latest intrinsic value of ?

The latest intrinsic value of as on 22 December 2024 is ₹4389.36, which is 19.71% lower than the current market price of ₹5,467.00. The stock has a market capitalization of 9,075 Cr. and recorded a high/low of 5,850/4,637 during the current fiscal year 2024-2025. As of Jun 2024, the company has reserves of ₹522 Cr and total liabilities of ₹794 Cr.

What is the Market Cap of ?

The Market Cap of is 9,075 Cr..

What is the current Stock Price of as on 22 December 2024?

The current stock price of as on 22 December 2024 is 5,467.

What is the High / Low of stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of stocks is 5,850/4,637.

What is the Stock P/E of ?

The Stock P/E of is 40.0.

What is the Book Value of ?

The Book Value of is 324.

What is the Dividend Yield of ?

The Dividend Yield of is 1.10 %.

What is the ROCE of ?

The ROCE of is 45.0 %.

What is the ROE of ?

The ROE of is 33.5 %.

What is the Face Value of ?

The Face Value of is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in . Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE